SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin receives USFDA's approval for generic version of Bayer's Beyaz Tablets

14 Jun 2018 Evaluate

Lupin has received final approval for its Drospirenone, Ethinyl Estradiol, Levomefolate Calcium Tablets and Levomefolate Calcium Tablets, 3 mg/0.02 mg/0.451 mg and 0.451 mg, from the United States Food and Drug Administration (USFDA) to market a generic version of Bayer HealthCare Pharmaceutical Inc.'s (Bayer) Beyaz Tablets.

Drospirenone, Ethinyl Estradiol, Levomefolate Calcium Tablets and Levomefolate Calcium Tablets, 3 mg/0.02 mg/0.451 mg and 0.451 mg had annual sales of around $82.2 million in the US (IQVIA MAT April 2018).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2525.95 36.10 (1.45%)
08-Jul-2026 09:31 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1926.75
Dr. Reddys Labs. 1381.05
Cipla 1468.40
Zydus Lifesciences 1179.05
Lupin 2525.95
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: